[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352574-105":59,"doc-detail-352574-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","phase-ib-multicenter-study-of-anti-tim-3-s095018sym023-in-combination-with-anti-pd-1-sym021-in-patients-with-advancedmetastatic-recurrent-biliary-tract-cancer","Phase Ib multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer","","TIM-3 is an inhibitory immune receptor associated with reduced antitumor activity, while PD-1 blockade can enhance antitumor responses. In this Phase Ib multicenter trial, S095018 (anti-TIM-3) combined with Sym021 (anti-PD-1) was evaluated in patients with advanced/metastatic recurrent biliary tract cancer progressing after systemic therapy and without prior PD-(L)1 inhibitor treatment. Thirty-five stage IV patients received treatment every 2 weeks; results showed modest clinical efficacy, manageable safety, and tumor-immune changes. ",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/phase-ib-multicenter-study-of-anti-tim-3-s095018sym023-in-combination-with-anti-pd-1-sym021-in-patients-with-advancedmetastatic-recurrent-biliary-tract-cancer/352574/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/phase-ib-multicenter-study-of-anti-tim-3-s095018sym023-in-combination-with-anti-pd-1-sym021-in-patients-with-advancedmetastatic-recurrent-biliary-tract-cancer/352574.png","ImageObject",300,407,{"name":92,"@type":93},"Mia  ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-19","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the primary focus of the Phase Ib multicenter study?","Question",{"text":112,"@type":113},"To evaluate S095018 (anti-TIM-3) in combination with Sym021 (anti-PD-1) in advanced/metastatic recurrent biliary tract cancer patients, including overall response rate and adverse events.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Who was eligible for enrollment in the study?",{"text":117,"@type":113},"Patients with advanced/metastatic biliary tract cancers whose disease progressed after at least one line of systemic therapy and who had not previously received PD-(L)1 inhibitors.",{"name":119,"@type":110,"acceptedAnswer":120},"What treatment interval and dosing were used?",{"text":121,"@type":113},"Sym021 was given at 3 mg/kg and S095018 at 10 mg/kg once every 2 weeks.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352574,1790472214,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687207024478,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Open access Original research  \n Phase Ib multicenter study of anti  \nTIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer  \nFrancois Ghiringhelli  ,1 Richard Kim,2 Teresa Macarulla,3 Irene Moreno  ,4 Albiruni Abdul Razak,5 Jordi Rodon Ahnert,6 Chih-Yi Liao,7 Sarah Lindsey Davis,8 Amit Mahipal,9 Thomas Marron,10 Judith Raimbourg,11 Hélène Kaplon,12  \nJulia Geronimi,12 Najah Harouki,12 Christelle Rodrigues,12 Pauline Darcel,12 Janus Schou Jakobsen,13 Niels Skartved,13 Rikke Hald,13  \nDaleen Lopez-Ravnborg,13 Peng He,14 Xenophon Ianopoulos,14  \nVasileios Askoxylakis,14 Nehal Lakhani  15  \nTo cite: Ghiringhelli F, Kim R, Macarulla T, et al. Phase Ib multicenter study of antiTIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer. Journal for ImmunoTherapy of Cancer 2026;14:e012344 . doi:10 . 1136/ jitc-2025-012344  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2025-012344](jitc-2025-012344)) .  \nAccepted 09 February 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nDr Francois Ghiringhelli; [fghiringhelli@cgfl.fr](fghiringhelli@cgfl.fr)  \nABSTRACT  \nBackground T-cell immunoglobulin and mucin-domain containing 3 (TIM-3) is an inhibitory receptor linked to decreased antitumor activity of immune cells. S095018 is a human anti-TIM-3 IgG2 antibody that blocks the binding of phosphatidyl serine to TIM-3. Sym021 is a humanized IgG1 antibody that inhibits the binding of programmed cell death protein-1 (PD-1) to its ligands programmed deathligand 1 (PD-L1) and PD-L2 .  \nMethods S095018 in combination with Sym021 was tested in patients with advanced/metastatic biliary tract cancers (BTC) whose disease progressed under treatment with at least 1 line of systemic therapy and who had not received prior treatment with PD-(L)1 inhibitors (NCT04641871) . Patients received 3 mg/kg of Sym021 and 10 mg/kg of S095018 once every 2 weeks. Primary endpoints included overall response rate and incidence/severity of adverse events. Key secondary endpoints included pharmacokinetics, immunogenicity assessment, progression-free survival (PFS) and overall survival (OS) .  \nResults 35 patients with stage IV BTC received S095018 in combination with Sym021 . A partial response was achieved in 2 patients (5 .7%) and stable disease in 11 patients (31 .4%) for a disease control rate of 37%; 4 patients were not evaluable for response. Median PFS and OS were 1.9 months (90% CI 1.8 to 3 .7) and 13.4 months (90% CI 8.2 to 27 . 1), respectively. The most common treatment-emergent adverse events of any grade included fatigue, pruritus, infusion-related reaction, and increases in amylase (8 .6% each) . Exploratory biomarker analyses in paired tumor biopsies showed an increase in intratumoral CD8 T-cell density and an upregulation of gene signatures related to interferon-γ signaling, antigen presentation, and T-cell activation with treatment without, however, clear association with efficacy endpoints.  \nConclusions Dual PD-1/TIM-3 inhibition was tolerable but exhibited modest antitumor activity in patients with  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n\n| ⇒ Current evidence suggests that the engagement of the galectin-9/T-cell immunoglobulin and mucindomain containing 3 (TIM-3) pathway may impair T-cell cytotoxicity in biliary tract cancers (BTC) .\u003Cbr>WHAT THIS STUDY ADDS |\n| --- |\n| ⇒ This is the first clinical trial to investigate the combination of an anti-programmed cell death protein-1 (PD-1) antibody with a TIM-3-targeting antibody inpatients with advanced/metastatic BTC, whose disease progressed under treat","cbCaiuJlzies6KDj","https://ap.wps.com/l/cbCaiuJlzies6KDj","pdf",865551,13,"English","# Background\n# Methods\n# Results\n# Conclusions\n# What is already known on this topic\n# What this study adds\n# How this study might affect research, practice or policy\n# Background","[{\"question\":\"What was the primary focus of the Phase Ib multicenter study?\",\"answer\":\"To evaluate S095018 (anti-TIM-3) in combination with Sym021 (anti-PD-1) in advanced/metastatic recurrent biliary tract cancer patients, including overall response rate and adverse events.\"},{\"question\":\"Who was eligible for enrollment in the study?\",\"answer\":\"Patients with advanced/metastatic biliary tract cancers whose disease progressed after at least one line of systemic therapy and who had not previously received PD-(L)1 inhibitors.\"},{\"question\":\"What treatment interval and dosing were used?\",\"answer\":\"Sym021 was given at 3 mg/kg and S095018 at 10 mg/kg once every 2 weeks.\"}]","Phase Ib multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer | PDF",1790100321,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2c3782c7111facc4adb260b020a32eb5.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dc1d8d96feb6a14474df4e3cb257c084.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aa75518f25efbd32c3036ccb3239f6e0.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1d76b48bccbea60c65c88432a2091959.webp",980,1306]